<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027347</url>
  </required_header>
  <id_info>
    <org_study_id>UMCHoChiMinh</org_study_id>
    <nct_id>NCT05027347</nct_id>
  </id_info>
  <brief_title>Detection of Plasma Circulating Tumor DNA in Gastric Cancer</brief_title>
  <official_title>Detection of Plasma Circulating Tumor DNA in Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Ho Chi Minh City (UMC)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Ho Chi Minh City (UMC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to develop a protocol for detection of circulating tumor DNA (ctDNA)&#xD;
      in plasma of patients with early stages of gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer (GC) is the fifth most common cancer worldwide and the third leading cause of&#xD;
      cancer deaths. Earlier detection of GC can dramatically increases the five-year survival rate&#xD;
      up to &gt; 90%. The current endoscopy and tissue biopsy remain excessively expensive for&#xD;
      middle-income nations, in addition to being fairly invasive, with possible complications.&#xD;
      Additionally, most of serum-based biomarkers such as carcinoembryonic antigen (CEA),&#xD;
      carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 72-4 (CA72-4), and carbohydrate&#xD;
      antigen 125 (CA125) are not recommended for detection of GC due to the limit of specificity&#xD;
      and sensitivity in the early stages of GC. Thus, it is essential to identify new biomarkers&#xD;
      for diagnosis of early stages of GC. In this study, the investigators develop an ultradeep&#xD;
      massive parallel sequencing (MPS) assay to detect tumor derived mutations (TDM) in plasma of&#xD;
      early stages of GC. This study provides proof-of-principle for eventual clinical employment&#xD;
      of circulating DNA, via liquid biopsy, for detection of early stages of GC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The sensitivity and and specificity of our mutation-based assay for detecting early-stage gastric cancer patients</measure>
    <time_frame>1 months after collecting blood and specimen</time_frame>
    <description>sensitivity and and specificity of our mutation-based assay for detecting early-stage gastric cancer patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Limit of detection (LOD): the lowest variant allelic frequency that can be reliably detected</measure>
    <time_frame>1 months after collecting blood and specimen</time_frame>
    <description>the lowest variant allelic frequency that can be reliably detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concordance rate of mutation results between plasma and tissue biopsy assay</measure>
    <time_frame>1 months after collecting blood and specimen</time_frame>
    <description>The concordance rate of mutation results between plasma and tissue biopsy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Circulating Tumor DNA (ctDNA)</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>100 healthy people</arm_group_label>
    <description>10 ml blood and tissue biopsy were collected from each patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 gastric cancer patients</arm_group_label>
    <description>10 ml blood and tissue biopsy were collected from each patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>plasma circulating tumor DNA</intervention_name>
    <description>A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer</description>
    <arm_group_label>100 gastric cancer patients</arm_group_label>
    <arm_group_label>100 healthy people</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with early and locally advanced stage (I, II and IIIA) gastric cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female patients aged 18 years and older&#xD;
&#xD;
          2. Histologically proven stage (I, II and IIIA) gastric adenocarcinoma&#xD;
&#xD;
          3. Naivety to treatment.&#xD;
&#xD;
          4. No known other concomitant cancer diagnosis&#xD;
&#xD;
          5. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pathologically late stage (stage IIIB and IV) or metastatic gastric adenocarcinoma&#xD;
&#xD;
          2. Underwent any type of treatment&#xD;
&#xD;
          3. Unable to undergo biopsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Long D. Vo, MD.</last_name>
    <phone>+84918133915</phone>
    <email>long.vd@umc.edu.vn</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Ho Chi Minh City</name>
      <address>
        <city>Ho Chi Minh City</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Long D. Vo, MD.</last_name>
      <phone>+84.918133915</phone>
      <email>long.vd@umc.edu.vn</email>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

